Grants, awards and news

Dear Reader,

within this newsletter we would like to inform you about the grants and awards, which TherapySelect and its cooperation partners received this year, as well as about further news.

Grants of TherapySelect

• We are very pleased that we received a grant from the EIT Health Headstart Programm. With the help of this grant the current radioactive version of the CTR-Test should be converted to a non-radioactive version. Thereby international commercialization should be facilitated. 

Additional information:

https://www.eithealth.eu/-/eit-health-germany-will-fund-six-promising-start-ups-with-innovative-solutions-for-healthcare-and-disease-control  

• To accelerate international commercialization of the CTR-Test we take part in the GoGlobal Programm of EIT Health.

Additional information:

https://eit.europa.eu/newsroom/eit-health-goglobal-medtech-accelerator

• We are also pleased that we received a PERMIDES Consultancy and Innovation Voucher together with dkd Internet Service GmbH. Within this grant we would like to develop a Disease Management Platform for our customers. This platform should be used for exchange of patient data, test results etc. according to data protection rules.

(There is no official press release yet at http://permides.eu/). 

Awards of TherapySelect

•  We received an award for a high quality presentation from the Eureka InnoVest Programm – Venture Forum Barcelona May 2017.

Additional Information:

http://2016.eurekainnovest.eu/events/awards_winners.aspx?events_id=1793

• We were invited to the European Venture Contest Final in Düsseldorf as well. From about 1250 companies which applied, we belonged to the 102 finalists, which could present their companies in front of investors.

Additional information:

https://www.techtour.com/events/2017/12/event-evc-final.html

Awards of Guardant Health

• The two founders of Guardant Health, Helmy Eltoukhy und AmirAli Talasaz, were selected for the 40 most influential young people in business under 40 from the Fortune magazine (“40 under 40“). 

Additional information:

http://fortune.com/40-under-40/

News about Paradigm Diagnostics

• The Paradigm Diagnostics Laboratory in Phoenix, Arizona added a fusion panel to the PCDx (Paradigm Cancer Diagnostic) test. Thereby the PCDx remains one of the most comprehensive molecular-based biomarker analysis for prediction of drug efficacy. In addition the laboratory was recently accredited by the College of American Pathologists (CAP). Furthermore, the laboratory is already CLIA (Clinical Laboratory Improvement Amendments) certified.

Additional information:

http://www.paradigmdx.com/news/

Trainings

• We offer trainings regarding our diagnostics for interested customers. This is intended to discover the diagnostics and their area of application and to obtain detailed information about them, respectively. These trainings can either take place as part of personal visits with a corresponding number of participants or as online meetings with single participants. If interested please contact us at the below-mentioned contact data.
  
  
  

Happy holidays and a happy new year 2018!

For further questions do not hesitate to contact our team.
Tel: +49 (0)6221-8936-152 oder
Email: contact@therapyselect.de

Sincerely,
Your TherapySelect Team